Narlaprevir

Drug Profile

Narlaprevir

Alternative Names: SCH-900518

Latest Information Update: 05 Jan 2016

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antivirals; Dipeptides; Sulfones
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 Sep 2010 Merck completes a phase II trial in treatment-naive patients with genotype 1 chronic Hepatitis C in USA
  • 18 Apr 2010 Final efficacy data from the extension period of a phase I trial in Hepatitis C presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL-2010)
  • 03 Nov 2009 Interim efficacy data from the extension period of a phase I trial in Hepatitis C presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top